(pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 8, 2013, Pages 4009-4016

  Irwin, Nigel ^a   Frizelle, Pamela ^a   O'Harte, Finbarr P M ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Cholecystokinin (CCK); Diabetes; High fat; Insulin sensitivity; Obesity; PEGylation

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR; GLUCOSE; GLUTAMYLGLUTAMINE CHOLECYSTOKININ OCTAPEPTIDE; INSULIN; MACROGOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYMATIC DEGRADATION; FOOD INTAKE; GLUCOSE TOLERANCE; INSULIN LIKE ACTIVITY; INSULIN SENSITIVITY; LIPID DIET; LIPID STORAGE; MALE; METABOLISM; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SATIETY; WEIGHT REDUCTION;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS; EATING; INSULIN; INSULIN RESISTANCE; MALE; MICE; OBESITY; POLYETHYLENE GLYCOLS; SINCALIDE;

MUS;

EID: 84877674398     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2013.04.004     Document Type: Article

References (33)

1. A.C. Ivy, and E. Oldberg A hormone mechanism for gallbladder contraction and evacuation Am. J. Physiol. 65 1928 599 613
2. I. Verbaeys, F. León-Tamariz, J. Buyse, M. De Cuyper, H. Pottel, M. Van Boven, and M. Cokelaere PEGylated cholecystokinin prolongs satiation in rats: dose dependency and receptor involvement Br. J. Pharmacol. 152 2007 396 403 (Pubitemid 47511254)
3. A. Heldsinger, G. Grabauskas, I. Song, and C. Owyang Synergistic interaction between leptin and cholecystokinin in the rat nodose ganglia is mediated by PI3K and STAT3 signaling pathways: implications for leptin as a regulator of short term satiety J. Biol. Chem. 286 2011 11707 11715
4. B. Ahrén, M. Pettersson, K. Uvnäs-Moberg, M. Gutniak, and S. Efendic Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man Diabetes Res. Clin. Pract. 13 1991 153 161
5. J.A. Lavine, P.W. Raess, D.S. Stapleton, M.E. Rabaglia, J.I. Suhonen, K.L. Schueler, J.E. Koltes, J.A. Dawson, B.S. Yandell, L.C. Samuelson, M.C. Beinfeld, D.B. Davis, M.K. Hellerstein, M.P. Keller, and A.D. Attie Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival Endocrinology 151 2010 3577 3588
6. J.F. Rehfeld, L. Friis-Hansen, J.P. Goetze, and T.V. Hansen The biology of cholecystokinin and gastrin peptides Curr. Top. Med. Chem. 7 2007 1154 1165 (Pubitemid 47040503)
7. M. Dufresne, C. Seva, and D. Fourmy Cholecystokinin and gastrin receptors Physiol. Rev. 86 2006 805 847 (Pubitemid 44033383)
8. F.P. O'Harte, M.H. Mooney, C.M. Kelly, and P.R. Flatt Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation Diabetes 47 1998 1619 1624 (Pubitemid 28445351)
9. N. Irwin, P. Frizelle, I.A. Montgomery, R.C. Moffett, F.P.M. O'Harte, and P.R. Flatt Beneficial effects of the novel choleycystokinin agonist (pGlu-Gln)-CCK-8 in animal models of obesity-diabetes Diabetologia 55 2012 2747 2758
10. N. Irwin, P. Frizelle, F.P. O'Harte, and P.R. Flatt Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal mice J. Endocrinol. 206 2013 53 59
11. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discov. 2 2003 214 221 (Pubitemid 37361666)
12. I. Verbaeys, F. León-Tamariz, J. Buyse, E. Decuypere, H. Pottel, and M. Cokelaere Lack of tolerance development with long-term administration of PEGylated cholecystokinin Peptides 30 2009 699 704
13. F.M. Veronese Peptide and protein PEGylation: a review of problems and solutions Biomaterials 22 2001 405 417 (Pubitemid 32007845)
14. F. León-Tamariz, I. Verbaeys, M. Van Boven, M. De Cuyper, J. Buyse, E. Clynen, and M. Cokelaere PEGylation of cholecystokinin prolongs its anorectic effect in rats Peptides 28 2007 1003 1011 (Pubitemid 46654440)
15. P. Caliceti, and F.M. Veronese Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv. Drug Deliv. Rev. 55 2003 1261 1277 (Pubitemid 37464561)
16. V.A. Gault, B.D. Kerr, N. Irwin, and P.R. Flatt C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes Biochem. Pharmacol. 75 Jun 2008 2325 2333
17. 3)GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy Br. J. Pharmacol. 155 2008 690 701
18. B.D. Kerr, P.R. Flatt, and V.A. Gault (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions Biochem. Pharmacol. 80 2010 1727 1735
19. B.D. Kerr, N. Irwin, P.R. Flatt, and V.A. Gault Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance Peptides 30 2009 219 225
20. B.D. Kerr, N. Irwin, F.P. O'Harte, C.J. Bailey, P.R. Flatt, and V.A. Gault Fatty acid derivatised analogs of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties Biochem. Pharmacol. 78 2009 1008 1016
21. N.H. McClenaghan, C.R. Barnett, E. Ah-Sing, Y.H. Abdel-Wahab, F.P. O'Harte, T.W. Yoon, S.K. Swanston-Flatt, and P.R. Flatt Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion Diabetes 45 1996 1132 1140 (Pubitemid 26260168)
22. P.R. Flatt, and C.J. Bailey Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice Diabetologia 20 1981 573 577 (Pubitemid 11096955)
23. N. Irwin, I.A. Montgomery, R.C. Moffett, and P.R. Flatt Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice Biochem. Pharmacol. 85 2013 81 91
24. F.M. Veronese, and G. Pasut PEGylation, successful approach to drug delivery Drug Discov. Today 10 2005 1451 1458 (Pubitemid 41483874)
25. C.M. Lo, S. Obici, H.H. Dong, M. Haas, D. Lou, D.H. Kim, M. Liu, D. D'Alessio, S.C. Woods, and P. Tso Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice Diabetes 60 2011 2000 2007
26. I.A. Montgomery, N. Irwin, and P.R. Flatt Beneficial effects of (pGlu-Gln)-CCK-8 on energy intake and metabolism in high fat fed mice are associated with alterations of hypothalamic gene expression Horm. Metab. Res. 2013 (in press, Epub ahead of print)
27. G.N. Ervin, and M.N. Teeter Cholecystokinin octapeptide and lithium produce different effects on feeding and taste aversion learning Physiol. Behav. 36 1986 507 512 (Pubitemid 16155423)
28. I. Verbaeys, F. León-Tamariz, H. Pottel, E. Decuypere, Q. Swennen, and M. Cokelaere PEGylated cholecystokinin is more potent in inducing anorexia than conditioned taste aversion in rats Br. J. Pharmacol. 155 2008 417 423
29. J.N. Crawley, and M.C. Beinfeld Rapid development of tolerance to the behavioural actions of cholecystokinin Nature 302 1983 703 706 (Pubitemid 13120271)
30. D.B. West, M.R. Greenwood, K.A. Marshall, and S.C. Woods Lithium chloride, cholecystokinin and meal patterns: evidence that cholecystokinin suppresses meal size in rats without causing malaise Appetite 8 1987 221 227
31. M. Covasa Deficits in gastrointestinal responses controlling food intake and body weight Am. J. Physiol. Regul. Integr. Comp. Physiol. 299 2010 R1423 R1439
32. B.R. Gedulin, S.E. Nikoulina, P.A. Smith, G. Gedulin, L.L. Nielsen, A.D. Baron, D.G. Parkes, and A.A. Young Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight Endocrinology 146 2005 2069 2076 (Pubitemid 40396918)
33. B.P. Cummings, K.L. Stanhope, J.L. Graham, D.G. Baskin, S.C. Griffen, C. Nilsson, A. Sams, L.B. Knudsen, K. Raun, and P.J. Havel Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats Diabetes 59 2010 2653 2661